Facebook
Britain's News Portal
Around The Clock
BREAKING
Loading latest headlines…

CAR-T cell therapy shows promise for stiff person syndrome in trial

A clinical trial of CAR-T cell therapy has shown significant success in treating stiff person syndrome (SPS), a rare neurological condition. Two participants regained essential daily capabilities after receiving the single-dose treatment.

  • CAR-T cell therapy, an immunotherapy, showed significant success in a clinical trial for stiff person syndrome (SPS).
  • Two trial participants recovered essential everyday capabilities previously lost to SPS after a single dose.
  • The treatment trains the body's immune system to identify and destroy disease-causing cells.

A form of immunotherapy known as CAR-T cell therapy has demonstrated significant success in treating patients with stiff person syndrome (SPS), a progressive neurological condition. This treatment, which trains the body's immune system to target and eliminate disease-causing cells, was administered in a recent clinical trial.

Two participants in the US trial, Jonathan Walden and Shari St Germain, recovered essential everyday capabilities that SPS had previously taken away. Mr. Walden, who had relied on family for help with walking and daily tasks, has since resumed working and participating in activities like hunting and fishing. Ms. St Germain, diagnosed in 2021, experienced improvements such as being able to walk on a treadmill again after the treatment.

Dr. Anastasia Zekeridou, a neurologist and researcher at Mayo Clinic, which led the trial, noted the striking degree of improvement in some patients. Dr. Sean Pittock, chairman of the department of neurology at Mayo Clinic, highlighted the potential of CAR-T therapy in autoimmune neurological diseases, offering hope for SPS patients and those with other immune-mediated neurological conditions.

SPS is a rare neurological disorder that gradually worsens, causing physical stiffness throughout the body. It is believed to be an autoimmune condition, affecting an estimated 8,000 people worldwide, with symptoms typically developing between the ages of 20 and 60.

Why this matters: The early results offer hope for people living with stiff person syndrome, a rare and incurable neurological condition for which effective treatment options are limited.

Related Articles

Get the news that matters.

Join thousands of readers getting the best of British news straight to their inbox.